Repositorio Dspace

Final Results From the ATALANTE/ENGOT-ov29 Randomized Phase III Trial of Atezolizumab, Bevacizumab, and Platinum-Based Therapy for Late-Relapsing Recurrent Ovarian Cancer

Mostrar el registro sencillo del ítem

dc.contributor.author Kurtz, Jean-Emmanuel
dc.contributor.author Pujade-Lauraine, Eric
dc.contributor.author Oaknin, Ana
dc.contributor.author Belin, Lisa
dc.contributor.author Grimm, Christoph
dc.contributor.author Kocián, Roman
dc.contributor.author Denys, Hannelore
dc.contributor.author Rosengarten, Ora-S
dc.contributor.author Follana, Philippe
dc.contributor.author Sehouli, Jalid
dc.contributor.author Martínez-García, Jerónimo
dc.contributor.author Alexandre, Jérôme
dc.contributor.author Hardy-Bessard, Anne-Claire
dc.contributor.author Frenel, Jean-Sébastian
dc.contributor.author Sabatier, Renaud
dc.contributor.author Gladieff, Laurence
dc.contributor.author De-la-Motte-Rouge, Thibault
dc.contributor.author Bonichon-Lamichhane, Nathalie
dc.contributor.author Kalbacher, Elsa
dc.contributor.author Heitz, Florian
dc.contributor.author Kurtz, J-E
dc.contributor.author Abadie-Lacourtoisie, S
dc.contributor.author Abdeddaim, C
dc.contributor.author Affi, R
dc.contributor.author Alexandre, J
dc.contributor.author Augereau, P
dc.contributor.author Avenin, D
dc.contributor.author Azemar, M
dc.contributor.author Baba-Hamed, N
dc.contributor.author Bally, O
dc.contributor.author Bazan, F
dc.contributor.author Boughalem, E
dc.contributor.author Brachet, P-E
dc.contributor.author Cappiello-Bataller, MA
dc.contributor.author Castanie, H
dc.contributor.author Chaigneau, L
dc.contributor.author Comte, A
dc.contributor.author Cottu, PH
dc.contributor.author De-la-Motte-Rouge, T
dc.contributor.author D'Hondt, V
dc.contributor.author Dillies-Legrain, AF
dc.contributor.author Extra, J-M
dc.contributor.author Frenel, JS
dc.contributor.author Freyer, G
dc.contributor.author Hardy-Bessard, A-C
dc.contributor.author Kaminsky, M-C
dc.contributor.author Lotz, J-P
dc.contributor.author Moulin, J-F
dc.contributor.author Mouret-Reynier, M-A
dc.contributor.author Ray-Coquard, I
dc.contributor.author De-la-Mothe, P-Regnault
dc.contributor.author Vano, YA
dc.contributor.author You, B
dc.contributor.author Grischke, E-M
dc.contributor.author Park-Simon, T-W
dc.contributor.author Alarcon, JD
dc.contributor.author Herrero, A-Alonso
dc.contributor.author García, J-Martínez
dc.contributor.author Sevelda, U
dc.date.accessioned 2026-11-11T09:05:18Z
dc.date.available 2026-11-11T09:05:18Z
dc.date.issued 2026-07
dc.identifier.citation Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Grimm C, Kocián R, et al. Final Results From the ATALANTE/ENGOT-ov29 Randomized Phase III Trial of Atezolizumab, Bevacizumab, and Platinum-Based Therapy for Late-Relapsing Recurrent Ovarian Cancer. JCO Oncol Adv. julio de 2026;3(3):e2600030. doi:10.1200/OA-26-00030
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29153
dc.description.abstract PURPOSE Previously reported results from the placebo-controlled double-blind randomized phase III ATALANTE/ENGOT-ov29 trial (ClinicalTrials.gov identifier: NCT02891824 ) showed that progression-free survival improvement with the addition of atezolizumab to standard bevacizumab and platinum-based chemotherapy for late-relapsing recurrent ovarian cancer did not reach statistical significance in the intention-to-treat (ITT; hazard ratio [HR] 0.83 [95% CI, 0.69 to 0.99]; two-sided P = .041) or PD-L1-positive populations (dual primary end points). Here we report the final analysis, including overall survival (OS). PATIENTS AND METHODS Patients with recurrent epithelial ovarian cancer, one or two prior chemotherapy lines, and platinum-free interval (PFI) >6 months were randomly assigned 2:1 to atezolizumab or placebo for up to 24 months, combined with bevacizumab and six cycles of investigator-selected platinum-based chemotherapy, stratified by PFI, PD-L1 status, and chemotherapy regimen. OS was a secondary end point. RESULTS At 5 years' median follow-up, the median OS was 35.8 months with atezolizumab-containing therapy (n = 410) and 30.6 months with standard therapy (n = 204) in the ITT population (HR, 0.83 [95% CI, 0.69 to 0.98]); 5-year OS rates were 27% versus 17%, respectively. Time to second subsequent therapy showed consistent results favoring atezolizumab. There was no evidence of an enhanced treatment effect in the PD-L1-positive population. CONCLUSION At the final analysis, a clinically meaningful 5-month improvement in median OS was observed with atezolizumab added to bevacizumab and a platinum doublet.
dc.language.iso eng
dc.publisher AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es *
dc.title Final Results From the ATALANTE/ENGOT-ov29 Randomized Phase III Trial of Atezolizumab, Bevacizumab, and Platinum-Based Therapy for Late-Relapsing Recurrent Ovarian Cancer
dc.type info:eu-repo/semantics/article
dc.relation.publisherversion https://ascopubs.org/doi/10.1200/OA-26-00030
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1200/oa-26-00030
dc.journal.title JCO Oncology Advances


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta